| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A074 | Tremelimumab Biosimilar (Anti-CTLA-4 / CD152 Reference Antibody) Featured | Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research. |
.png)
|
| A075 | Vunakizumab Biosimilar (Anti-CTLA-8 / IL-17a Reference Antibody) Featured | Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. |
.png)
|
| A076 | Perakizumab Biosimilar (Anti-CTLA-8 / IL-17a Reference Antibody) Featured | Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis. |
.png)
|
| A077 | Netakimab Biosimilar (Anti-CTLA-8 / IL-17a Reference Antibody) Featured | Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis. |
.png)
|
| A078 | Med. Bio. Labs patent anti-CXADR Biosimilar (Anti-CXADR Reference Antibody) Featured |
|
|
| A079 | Genentech patent anti-IL-8 Biosimilar (Anti-CXCL8 / IL-8 Reference Antibody) Featured |
|
|
| A080 | Roche patent anti-CCN1 Biosimilar (Anti-CYR61 / CCN1 Reference Antibody) Featured |
|
|
| A081 | Dragonfly patent anti-DLL3 Biosimilar （Anti-DLL3 Reference Antibody） Featured |
|
|
| A082 | Begelomab Biosimilar （Anti-DPP4 / CD26 Reference Antibody） Featured | Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. |
.png)
|
| A083 | Citatuzumab Biosimilar（Anti-EpCAM / TROP1 / CD326 Reference Antibody） Featured |
|
|
| A084 | MEDI-547 Biosimilar（Anti-EphA2 Reference Antibody） Featured |
|
|
| A085 | Sanofi Aventis patent anti-EphA2 Biosimilar（Anti-EphA2 Reference Antibody） Featured |
|
|
| A086 | Disitamab Biosimilar（Anti-ERBB2 / HER2 / CD340 Reference Antibody） Featured | Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)). |
.png)
|
| A087 | Tisotumab Biosimilar（Anti-F3 / Factor III / Tissue Factor / CD142 Reference Antibody） Featured | Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. |
.png)
|
| A088 | TNX-832 Biosimilar（Anti-F3 / Factor III / Tissue Factor / CD142 Reference Antibody ） Featured |
|
|
| A089 | Novo Nordisk patent anti-Factor VIII Biosimilar（Anti-F8 / Factor VIII Reference Antibody） Featured |
|
|
| A090 | Emicizumab Biosimilar（Anti-F9 / Factor IX Reference Antibody） Featured | Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research. |
|
| A091 | Sibrotuzumab Biosimilar（Anti-FAP Reference Antibody） Featured | Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC). |
.png)
|
| A092 | VIB9600 Biosimilar(Anti-FcgR2a / CD32a Reference Antibody) Featured |
|
|
| A093 | Cevostamab Biosimilar(Anti- FcRH5 / IRTA2 / CD307e Reference Antibody) Featured | Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells. |
.png)
|
| A094 | DFRF4539A Biosimilar(Anti- FcRH5 / IRTA2 / CD307e Reference Antibody) Featured |
|
|
| A095 | Rozanolixizumab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody) Featured | Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. |
.png)
|
| A096 | STX-100 Biosimilar(Anti-Integrin aVb6 (ITGAV & ITGB6) Reference Antibody) Featured |
|
|
| A097 | Abrilumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody) Featured | Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD). |
.png)
|
| A098 | Batoclimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody) Featured | Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies. |
.png)
|
| A099 | 1A6 Biosimilar(Anti-FGF19 Reference Antibody) Featured |
|
|
| A100 | HuGAL-F2 Biosimilar(Anti-FGF2 Reference Antibody) Featured |
|
|
| A101 | Burosumab Biosimilar(Anti-FGF23 Reference Antibody) Featured | Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. |
.png)
|
| A102 | Lilly patent anti-FGFR-1 Biosimilar(Anti-FGFR1 / CD331 Reference Antibody) Featured |
|
|
| A103 | Aprutumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody) Featured | Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. |
.png)
|
